Cargando…

Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study

OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient fil...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsobhi, Enaam M., Farahat, Fayssal M., Daghistani, Mustafa F., Awad, Khadeeja A., Al-Zahrani, Omar S., Al-Saiari, Afaf S., Koshak, Fai K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901761/
https://www.ncbi.nlm.nih.gov/pubmed/31707416
http://dx.doi.org/10.15537/smj.2019.11.24584
_version_ 1783477555367510016
author Alsobhi, Enaam M.
Farahat, Fayssal M.
Daghistani, Mustafa F.
Awad, Khadeeja A.
Al-Zahrani, Omar S.
Al-Saiari, Afaf S.
Koshak, Fai K.
author_facet Alsobhi, Enaam M.
Farahat, Fayssal M.
Daghistani, Mustafa F.
Awad, Khadeeja A.
Al-Zahrani, Omar S.
Al-Saiari, Afaf S.
Koshak, Fai K.
author_sort Alsobhi, Enaam M.
collection PubMed
description OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient files between 2011 and 2018. Sixty-three patients were excluded due to pediatric age and secondary AML. The remaining 87 adult patients with de novo AML were enrolled in this study. RESULTS: The most frequent cytogenetic abnormalities were t(15;17) (17.2%), followed by complex cytogenetic (13.8%) and t(8;21) (5.7%). The most frequent molecular abnormalities were promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) (16.1%) and Nucleophosmin 1 (NPM1) (11.5%). The highest OS rate was associated with t(15;17), PML-RARA, and NPM. However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate. CONCLUSION: The study describes cytogenetic and molecular abnormalities observed in adult AML patients and gives an overview of prognostic factors and determine the OS, with comparable results with recent published data by the WHO.
format Online
Article
Text
id pubmed-6901761
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-69017612021-02-26 Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study Alsobhi, Enaam M. Farahat, Fayssal M. Daghistani, Mustafa F. Awad, Khadeeja A. Al-Zahrani, Omar S. Al-Saiari, Afaf S. Koshak, Fai K. Saudi Med J Brief Communication OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient files between 2011 and 2018. Sixty-three patients were excluded due to pediatric age and secondary AML. The remaining 87 adult patients with de novo AML were enrolled in this study. RESULTS: The most frequent cytogenetic abnormalities were t(15;17) (17.2%), followed by complex cytogenetic (13.8%) and t(8;21) (5.7%). The most frequent molecular abnormalities were promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) (16.1%) and Nucleophosmin 1 (NPM1) (11.5%). The highest OS rate was associated with t(15;17), PML-RARA, and NPM. However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate. CONCLUSION: The study describes cytogenetic and molecular abnormalities observed in adult AML patients and gives an overview of prognostic factors and determine the OS, with comparable results with recent published data by the WHO. Saudi Medical Journal 2019-11 /pmc/articles/PMC6901761/ /pubmed/31707416 http://dx.doi.org/10.15537/smj.2019.11.24584 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Alsobhi, Enaam M.
Farahat, Fayssal M.
Daghistani, Mustafa F.
Awad, Khadeeja A.
Al-Zahrani, Omar S.
Al-Saiari, Afaf S.
Koshak, Fai K.
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title_full Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title_fullStr Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title_full_unstemmed Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title_short Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
title_sort overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901761/
https://www.ncbi.nlm.nih.gov/pubmed/31707416
http://dx.doi.org/10.15537/smj.2019.11.24584
work_keys_str_mv AT alsobhienaamm overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT farahatfayssalm overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT daghistanimustafaf overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT awadkhadeejaa overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT alzahraniomars overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT alsaiariafafs overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy
AT koshakfaik overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy